FDA Accepts Review of Eye Drop Aimed at Replacing Reading Glasses

Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia...

FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

/PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for...

South Korea's Presbyopia Market to Open with YUVEZZI, VIZZ

South Koreas Presbyopia Market to Open with YUVEZZI, VIZZ The market for presbyopia eye drops, which can improve vision clarity with just one drop of

The Future of Yuvezzi Eye Drops in Presbyopia, With John Hovanesian, MD

Hovanesian breaks down the process by which Yuvezzi received FDA approval and discusses the prescription and application of the new drug.

Viatris, Opus Genetics’ Investigational Phentolamine Ophthalmic Solution Demonstrates Strong Results in Presbyopia Trial

Results from the Phase III VEGA-3 trial show that a significantly higher number of patients with presbyopia who received MR-141 achieved a ≥3-line gain in binocular near visual acuity without compromising distance vision compared to placebo.

FDA Accepts Viatris Supplemental Application for Phentolamine Eye Drops to Treat Presbyopia

Viatris Inc. announced that the U.S. Food and Drug Administration has accepted for review its supplemental New Drug Application for MR-141 (phentolamine ophthalmic solution 0.75%)Search drug to treat presbyopia disease, an age-related vision condition affecting nearly 128 million Americans. The FDA has assigned a PDUFA goal date of October 17, 2026, for its regulatory decision.